Treatment with the anti-vascular endothelial growth factor (VEGF) antibody (Bevacizumab) has reportedly resulted in tumor control and hearing improvement in NF2 patients [19,20]. This evidence concerns the gene VEGFA and NF2-related schwannomatosis.